Spyre Therapeutics (NASDAQ:SYRE - Free Report) had its price target upped by Guggenheim from $50.00 to $65.00 in a research report report published on Friday, Benzinga reports. They currently have a buy rating on the stock.
Several other research analysts also recently weighed in on the company. Evercore ISI began coverage on Spyre Therapeutics in a research note on Tuesday, July 16th. They set an "outperform" rating on the stock. Wedbush started coverage on Spyre Therapeutics in a report on Wednesday, September 4th. They issued an "outperform" rating and a $45.00 price target for the company. Ten analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $46.43.
Get Our Latest Stock Analysis on SYRE
Spyre Therapeutics Price Performance
Shares of SYRE stock traded up $1.11 during mid-day trading on Friday, hitting $34.81. 537,120 shares of the stock traded hands, compared to its average volume of 513,232. Spyre Therapeutics has a 52-week low of $8.43 and a 52-week high of $47.97. The stock has a market cap of $1.40 billion, a P/E ratio of -0.49 and a beta of 2.92. The stock's fifty day moving average is $29.09 and its two-hundred day moving average is $30.46.
Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) last posted its earnings results on Wednesday, August 7th. The company reported ($0.86) EPS for the quarter, beating analysts' consensus estimates of ($0.90) by $0.04. As a group, equities analysts forecast that Spyre Therapeutics will post -3.68 EPS for the current fiscal year.
Institutional Investors Weigh In On Spyre Therapeutics
Institutional investors and hedge funds have recently modified their holdings of the company. Driehaus Capital Management LLC acquired a new position in Spyre Therapeutics in the 2nd quarter worth approximately $16,153,000. Ensign Peak Advisors Inc acquired a new stake in Spyre Therapeutics during the 2nd quarter valued at approximately $1,939,000. Bank of New York Mellon Corp purchased a new stake in shares of Spyre Therapeutics in the 2nd quarter valued at $2,767,000. Rhumbline Advisers acquired a new stake in shares of Spyre Therapeutics in the second quarter worth $1,220,000. Finally, Armistice Capital LLC purchased a new position in shares of Spyre Therapeutics during the second quarter worth $3,197,000. Institutional investors and hedge funds own 80.39% of the company's stock.
Spyre Therapeutics Company Profile
(
Get Free Report)
Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).
Further Reading
Before you consider Spyre Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spyre Therapeutics wasn't on the list.
While Spyre Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
